Neurocrine launches free interactive courses to improve healthcare providers' knowledge of classic congenital adrenal hyperplasia.

Neurocrine Biosciences introduced two free educational tools, bootCAHmp and DiscoverCAH, to help healthcare providers better understand and manage classic congenital adrenal hyperplasia (CAH), a rare genetic disorder. bootCAHmp offers foundational clinical knowledge through interactive modules and real patient cases, while DiscoverCAH provides virtual patient scenarios for practical decision-making. These resources aim to address the challenges clinicians face due to limited exposure to CAH patients and support improved patient care. Both tools are accessible online and developed with expert endocrinologists.

Neurocrine Biosciences Inc (NBIX) shares are trading at USD 147.00 on Pluang, showing a modest 0.42% increase as of Oct 30, 2026 19:42 WIB. The stock's market cap stands at $14.88 billion, with a 52-week range between $123.10 and $185.50, reflecting steady investor interest in the health sector.